Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Notice of Amended and Restated Pricing Supplement

23rd Mar 2026 07:00

RNS Number : 5765X
Wells Fargo Bank N.A.
23 March 2026
 

23 March 2026

NOTICE OF AMENDED AND RESTATED PRICING SUPPLEMENT

WELLS FARGO BANK, NATIONAL ASSOCIATION

U.S.$10,000,000,000

Euro Medium Term Note Programme

 

HKD 870,000,000 3.16 per cent. Notes due 17 March 2031 (Series 48; ISIN: XS3318845297; Common Code: 331884529) (the "Notes")

 

This notice ("Notice") is supplemental to, and should be construed together with the Information Memorandum dated 2 March 2026 relating to the U.S.$10,000,000 Euro Medium Term Note Programme of Wells Fargo Bank, National Association and the pricing supplement dated 13 March 2026 relating to the Notes (the "Original Pricing Supplement").

The Issuer hereby gives notice to all Noteholders that the Original Pricing Supplement has been amended and restated (the "Amended and Restated Pricing Supplement") with effect from 20 March 2026.

Specifically, for the purpose of correcting a manifest error, the item "Series Number" in paragraph 2 contained in "Part A - Contractual Terms" of the Original Pricing Supplement has been deleted in its entirety and replaced with the following:

"2.

Series Number:

48"

Terms defined in the Amended and Restated Pricing Supplement have the same meaning when used in this Notice.

To view the full document, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/5765X_1-2026-3-20.pdf

WELLS FARGO BANK, NATIONAL ASSOCIATION

For further information, please contact

John Beer

Senior Company Counsel

Wells Fargo & Company

+1-415-396-5826

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the Amended and Restated Pricing Supplement and/or the information memorandum dated 18 September 2023 relating to the above-mentioned programme ( the "Information Memorandum") may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Amended and Restated Pricing Supplement and/or the Information Memorandum) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Amended and Restated Pricing Supplement and/or the Information Memorandum is not addressed. Prior to relying on the information contained in the Amended and Restated Pricing Supplement and/or the Information Memorandum you must ascertain from the Amended and Restated Pricing Supplement and/or the Information Memorandum whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCPPUBGWUPQPUU

Related Shares:

Wells Far Na 35
FTSE 100 Latest
Value10,436.29
Change71.50